Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

First-line Targeted Therapies in Metastatic CRC

July 14th 2016

Practical Application of Molecular Testing in CRC

July 14th 2016

Personalized Medicine in Colorectal Cancer

July 14th 2016

FDA Releases Draft Guidances on Next-Generation Sequencing

July 7th 2016

The FDA has issued two draft guidances that will provide regulatory oversight for the use of next-generation sequencing-based tests.

Dr. Kurian on Association of Ovarian Cancer Risk With Mutations Detected by Multiple-Gene Germline Sequencing

July 6th 2016

Allison W. Kurian, MD, MSc, associate professor of Medicine and of Health Research and Policy, Stanford University School of Medicine, discusses an ongoing trial exploring the association of ovarian cancer risk with mutations detected by multiple-gene germline sequencing in 95,561 women.

Daniel Sargent on International Collaboration for Colon Cancer Research

June 30th 2016

Daniel Sargent, PhD, professor of Oncology and Biostatistics, Mayo Clinic in Rochester, Minnesota, discusses the IDEA initiative, which is an international study to examine if patients with colon cancer would benefit from reducing the duration of adjuvant therapy from 3 months to 6 months to reduce side effects and cost.

Black Women Who Are BRCA Carriers Less Likely to Pursue Breast and Ovarian Cancer Risk Reduction

June 7th 2016

Young black women with breast cancer are much less likely to have BRCA testing or, if they carry a BRCA mutation, to undergo risk-reducing prophylactic mastectomy or salpingo-oophorectomy.

Dr. Hainsworth on Selecting Therapy Based on Genetics

June 5th 2016

John D. Hainsworth, MD, co-founder; principal investigator, Sarah Cannon Research Institute, discusses the results of the MyPathway trial, which was an open-label, phase IIa umbrella basket study.

Molecular Targeting Yields Responses in 12 Cancers in Off-Label Indications

June 5th 2016

Treating patients based on the presence of molecular abnormalities regardless of tumor type proved to be a promising strategy in an ongoing phase IIa umbrella basket study.

FDA Approves Novel Diagnostics for NSCLC, NETs

June 2nd 2016

The FDA has approved new diagnostic tests for the detection of somatostatin receptor-positive neuroendocrine tumors and for EGFR mutations from blood samples for patients with non–small cell lung cancer.

Communicating Breast Cancer Genetic Testing Results to Patients

May 31st 2016

Cost Considerations in Breast Cancer Genetic Testing

May 31st 2016

Breast Cancer and Genetic Counseling

May 31st 2016

Next-Generation Sequencing in Breast Cancer

May 31st 2016

Clinical Experience with Multi-Gene Panel Use in Breast Cancer

May 31st 2016

Assessing Breast Cancer Risk: Rationale for Multigene Panel Use

May 31st 2016

Understanding the Options in Multi-Gene Panels

May 31st 2016

Breast Cancer Risks: Guidelines for Genetic Testing

May 31st 2016

Mutations and the Risk for Breast Cancer

May 31st 2016

Value of Hereditary Breast Cancer Testing

May 31st 2016